INHIBITORS OF LEUKOTRIENE PRODUCTION

摘要

The present invention relates to compounds of formula (I):;;or a pharmaceutically acceptable salt thereof, wherein R1 is defined herein. The compounds of formula (I) are useful as inhibitors of leukotriene A4 hydrolase (LTA4H) and treating LTA4H related disorders. The present invention also relates to pharmaceutical compositions comprising the compounds of formula (I), methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.

主权项

1. A compound of formula (I):or a pharmaceutically acceptable salt thereof, wherein:
R1 is: (a) a group of formula —N(R2)(R3), wherein
R2 is selected from the group consisting of hydrogen, —(C1-C6)alkyl, and —(C3-C6)cycloalkyl;R3 is selected from the group consisting of hydrogen, —(C1-C6)alkyl, —(C3-C6)cycloalkyl, and -(4- to 7-membered)heterocyclyl,wherein each of said —(C1-C6)alkyl, —(C3-C6)cycloalkyl, and -(4- to 7-membered)heterocyclyl of said R3 may optionally be substituted by 1 to 3 groups independently selected from the group consisting of R4, —((C1-C6)alkylene)-R4, —C(O)—(C1-C6)alkyl, —C(O)—(C3-C6)cycloalkyl, and —C(O)—((C1-C6)alkylene)-R4;R4 is selected from the group consisting of halo, —OH, ═O, —NH2, —NH(C1-C6)alkyl, —N((C1-C6)alky)2, —(C1-C6)alkyl, —O(C1-C6)alkyl, —(C3-C6)cycloalkyl, and -(4- to 7-membered)heterocyclyl);wherein each of said R4 may optionally be substituted by 1 to 3 groups independently selected from the group consisting of —O(C1-C6)alkyl, and —(C3-C6)cycloalkyl;or (b) a 4- to 9-membered N-heterocyclic ring of formula: wherein said 4- to 9-membered N-heterocyclic ring optionally comprises one to three additional hetero-ring atoms selected from the group consisting of nitrogen, oxygen and sulfur atoms; and wherein said 4- to 9-membered N-heterocyclic ring is optionally substituted by 1 to 3 groups independently selected from the group consisting of R5, —((C1-C6)alkylene)-R5, —C(O)—(C1-C6)alkyl, —C(O)—(C3-C6)cycloalkyl, —C(O)—((C1-C6)alkylene)-R5, —C(O)—N(R6)—((C1-C6)alkylene)-R5, —C(O)—N(R6)(R6) and -(4- to 7-membered)heterocyclyl) optionally substituted by 1 to 3 R5 groups;each R5 is independently selected from the group consisting of halo, —OH, ═O, —N(R6)2, —N(R6)(C(O)—R6), —(C1-C6)alkyl, —O(C1-C6)alkyl, —(C3-C6)cycloalkyl, and -(4- to 7-membered)heterocyclyl); andeach R6 is independently selected from the group consisting of hydrogen and —(C1-C6)alkyl optionally substituted by —OH.